期刊
EXPERT OPINION ON INVESTIGATIONAL DRUGS
卷 18, 期 12, 页码 1843-1864出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543780903379530
关键词
anxiety; chemotherapy-induced emesis; clinical development; depression; irritable bowel syndrome; postoperative nausea and vomiting; schizophrenia; tachykinin antagonists
Tachykinins (TKs) are small peptides widely distributed in the central and peripheral nervous systems where they act as neurotransmitters. Potent and selective TKs antagonists have been developed in the last 20 years and many efforts have been made to prove their efficacy in the treatment of various diseases. Herein the most prominent results in the clinical development are reported and discussed. For aprepitant, the only compound of this class to have been launched to date, results of clinical studies and postmarketing cost-effectiveness data for the treatment of chemotherapy-induced emesis are discussed. The field is still well active, as currently proof-of-concept studies for indications initially missed (i.e., depression) are ongoing and new targets are under investigation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据